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1. Introduction
Q4 Tuberculosis (TB) nowadays is one of ‘‘global health
emergency’’ diseases.1 The increasing evidence in TB
patients associated with the rising number of patients at
risk for TB, i.e. patients with immunocompromised condi-
tion such patients with HIV, diabetes mellitus (DM), cancer
and autoimmune diseases. The TB infection at risk in
DM patients increased 2.39 times with the risk of failure of
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a b s t r a c t
Metformin (MET) is a potential Q2combination drug to elevate anti-TB efﬁcacy. However, the
clinical effect, especially smear reversion, during metformin applied with anti-tuberculosis
and insulin in patients with type 2 DM newly TB co-infection were remain unknown.
An observational clinical study was done in DM newly TB co-infection outpatients at
Surabaya Paru Hospital. This study evaluated MET therapy, at least 2 months, accompanying
with insulin and anti-TB regimens and compared to comparison group. The smear, micro-
tubule-associated Protein1 Light Chain 3B (MAP1LC3B) level, as the presentation of autop-
hagy, Superoxide Dismutase (SOD) level, Interferon (IFN)-g and Interleukin (IL)-10 levels
were evaluated twice.
From 42 participants in this study, 22 participants of observation group that received
additional MET therapy, 100% had sputum smear reversion after 2-months intensive phase
of anti-TB therapy. Whereas 25% of 20 participants of comparison group did not undergo
reversion inserts sputum smear.
As conclusion, MET has the Q3potential of being an additive combination therapy to
enhance the bactericidal effect of anti-TB on DM-TB coinfection patients. Metformin
enhances the effects of anti-TB and insulin therapy in increasing the smear reversion by
increasing autophagy.
© 2018 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.
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anti-TB therapy increased 1.69 times with the smear
reversion  60%.2,3
First-line anti-TB regiments, rifampicin, isoniazid (INH),
ethambutol, pyrazinamide, use as anti-TB, thus, those
etiology therapy aimed for curing the patients, preventing
death, preventing recurrence, cutting off the transmission
chains and preventing pathogen resistance by eradication
Mycobacterium tuberculosis.4–6 The effectiveness of anti-TB
are also inﬂuenced by the host immune response due to the
interaction of anti-TB. Adjunctive therapy with immuno-
modulators that enhance TB immunity (host-directed
therapy, HDT) could shorten treatment durations and
improve TB outcomes.7–9 The identiﬁcation of new host-
directed therapies aimed at improving the clinical outcome
of TB patients is a priority for TB management and WHO,
including some drugs that work on immune regulation.
Currently, several studies have been conducted to deter-
mine the function of some immunomodulatory agents,
including corticosteroids, TNF blockers, thalidomide, and
non-steroidal anti-inﬂammatory (NSAIDs) as adjunct of OAT
therapy.8,9
One of HDT mechanism is autophagy due to its ability in
inhibiting the TB infection process.8,9 The process of activating
autophagy from formation to maturation and then fusion with
lysosomes for phagolysosome or autophagy processes
requires many activators and protein (ATGs), one of the
proteins representing phagolysosome or autophagy is
MAP1LC3B/ATG8.
Metformin hydrochloride (MET), biguanide the oral
anti diabetic agent, recently, by a comprehensive in silico
study, MET known has possibilities of utilizing as a
combination drug with existing antibiotics for TB thera-
py10 and by an extensive in vitro study, MET was reported
controlling the growth of drug-resistant M. tuberculosis
strains via production of mitochondrial reactive oxygen
species and facilitates phagosome-lysosome fusion.11 Thus,
MET is known as one of highly potential HDT due to
target autophagy by AMPK activation or known as mTOR
inhibitor.11,12
Moreover, MET is not metabolized by P450 enzymes,4,13,14
thus it has no interaction with rifampicin that could decrease
the therapy efﬁcacy. However, interaction MET and rifampi-
cin increases the expression of organic cation transporter
(OCT1) and hepatic uptake of metformin, leading to an
enhanced glucose-lowering.4,5,14 MET is also expected en-
hanced isoniazid (INH) efﬁcacy due to SOD activity.15 INH a
pro-drug, its activation is requiring an interaction with Kat-G
produced by M. tuberculosis.4,14 Kat-G activation also pro-
duces oxidative stress – reactive oxygen species (ROS),
namely H2O2 and alkyl hydroperoxides. ROS is neutralized
by an antioxidant, superoxide dismutase (SOD).15,16 It is
suspected that SOD contributes to the INH-induced bacte-
ricidal effects.
However, the mechanism of immune response changes
due to the effects of metformin therapy to enhance the effect
of anti-TB was not yet clear. This study, due to clariﬁcation
aims, we measured the change levels of MAP1LC3B, SOD and
IFN-g levels before and after this observation period and as
clinical result, we also evaluated the smear reversion in DM-TB
coinfection patients.
2. Materials and methods
2.1. Study design
This involved type 2 DM-TB coinfection patients of observa-
tional clinical study and simple random allocation technique
with two groups, MET group and non MET group. The MET
group was the group receiving metformin therapy 1000–
1500 mg along with insulin and anti-TB during the intensive
periods, while non MET group received insulin and anti-TB
therapy. Patients were carried out at outpatient ward of
Surabaya Paru Hospital, with criterias: (1) patient DM with
new case of TB co-infection, whom were given insulin and TB
treatment regimens; (2) positive AFB in sputum smear; (3)
patient's age was 25–60 years old; (4) has normal liver
function and renal function; (5) not in hypoxia condition,
presenting by peripheral oxygen saturation level must be
higher than 92%.
The levels of MAP1LC3B, SOD and IFN-g was measured
before and after this observation period and as clinical result,
we also evaluated the smear reversion in DM-TB coinfection
patients in both of groups.
2.2. Diagnosis and management therapy
The diagnosis of TB was established by (1) clinical symptoms
and signs of TB, such: chronic productive cough, unintentional
weight loss; (2) positive sputum smear of acid-fast bacilli (AFB)
by microscopic Ziehl-Neelsen-stained sputum slides; and (3)
chest radiographs with suggestive features of TB. Diagnosis of
DM was established by fasting and 2 h after meal blood
glucose. HbA1c was measured after 2 months MET therapy, as
evaluation.
Patients diagnosed with TB were registered and treated
with anti-TB regimens for a period of 6 months in accordance
to WHO guidelines.17,18 Management therapy for achieving
good glycaemic control was insulin therapy. These following
drugs were used: MET (Metformin(R)), insulin (Humulin(R)),
rifampicin (RIF), isoniazid (INH), pyrazinamide (PYR), etham-
butol (ETH). MET were given 1000 – 1500 mg in divided daily
dose for at least two months or during intensive phase of anti-
TB.
2.3. AFB smears
Sputum smears were stained by the Ziehl-Nielsen technique
and examined by light microscopy for AFB. Sputum were
collected two times: (1) before treatment in order to diagnose
and (2) after intensive phase of anti-TB treatment in order to
evaluate the treatment.
2.4. Cells culture and ELISA
2.4.1. Cells
PBMC was obtained from patients' whole blood and 1  106
were cultured in RPMI 1640 medium supplemented with 10%
fetal bovine serum. Supernatant were harvested after 72 h and
prepare for ELISA methods in order to measure the levels of
MAP1LC3B, SOD and IFN-g.
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2.4.2. ELISA
MAP1LC3B (MyBioSource MBS760738); SOD (Biovision K335-
100); and IFN-g (RnD DIF50) were used as measurement kits.
3. Result and discussion
3.1. Characteristic of patients
This study's ethical clearance was approved by ethical
committee of Surabaya Paru Hospital with no. 09.01/KERS/
102.6/2016. During this study period, there were 476 cases of
new TB infection and 156 cases (30%) of that were type 2 DM
newly TB co-infection. 42 patients were eligible participated in
this observational studies. All the basic conditions in both
groups were homogenous (p > 0.05) (as seen in Table 1).
In order to prevent MET associated lacto acidosis (MALA)
during MET therapy in this study, all patients has been
determined at the precondition criterias as seen in Section 2.1.
Moreover, there was no incidence of lactic acidosis event
during this observation period.19
3.2. Acid fast bacilli smears
Sputum for AFB smears were collected two times: (1) before
treatment; and (2) after intensive phase of anti-TB therapy in
order to evaluate the treatment (Table 2).
Data in Table 2 shows that prior to intensive phase of anti-
TB therapy none of subjects were having negative AFB smear
in both groups. The highest number of AFB count (+3) in MET
group was 40.9% and in non MET group was 35%. After 2
months MET therapy accompanying with insulin and anti-TB
regimens, 100% of patient of MET group were AFB smear
reversion (negative AFB smears result), while only 75% of non
MET group had AFB smear reversion. Using the Fisher's exact
test, results of different test p = 0.046 ( p < 0.005), which means
there is a signiﬁcantly difference of AFB smears reversion
between the MET group and the Non MET group.
3.3. Level of MAP1LC3B, SOD, IFN-g
3.3.1. Autophagy
Autophagy is a fundamental process of cell biology intimately
involved in the interaction between M. tuberculosis and the
phagocytes, including macrophages, dendritic cells (DC) and
neutrophils. M. tuberculosis has capacity to evade the autop-
hagy of mononuclear phagocytes (MPs) and leverage the
intracellular environment as a replication niche.20,21 Com-
bined with hyperglycemia state and high free radicals of
oxygen or nitrogen, infected MPs of DM patients are faced with
a pathogen surviving in phagosomes that fail to incorporate
the molecular machinery and also fail to fuse with lysosomes
to expose bacilli, then, resulting the failure of anti-TB therapy
.22,23
Autophagy in TB infection is a combined response of innate
and adaptive host immune systems that are essential for the
process of M. tuberculosis elimination. Microtubule-associated
protein 1 light chain 3 (MAP1LC3B/ATG8) is ubiquitine-like
modiﬁer that represents autophago-lysosome fusion or better
known as autophagy,24 thus in this study MAP1LC3B was used
to represent autophagy activity.
MET is known as mTOR inhibitor, by the activation of AMPK
.9,12,25 Recent researches of MET that has been done in silico,
in vitro and animal's in vivo, expressed that MET is a potential
adjunct for anti-TB therapy.10,12,25
Table 3 shows that MAP1LC3B level before treatment
between MET group and non MET group were alike (
p > 0.005), thus it shows that patients in both groups, before
treatment, were in similar stage of MAP1LC3B. The differ-
ences before and after observation period was signiﬁcant in
MET group (p < 0.005) while in non MET group was not.
Moreover, compared to non MET group, the change of
MAP1LC3B after MET therapy during intensive period of
anti-TB and insulin was also signiﬁcant differences. Thus,
we concluded that MET improves autophagy and it results
100% AFB smear reversion rate in MET group (as seen in
Table 2).
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Table 2 – Acid fast bacilli smears result of type 2 DM-TB patients before and after observation period.
AFB result MET group (N %) Non MET group (N %)
Before After Before After
Negative 0 (0%) 22 (100%) 0 (0%) 15 (75%)
Scanty/+1 9 (40.9%) 0 (0%) 6 (30%) 5 (25%)
+2 4 (18.2%) 0 (0%) 7 (35%) 0 (0%)
+3 9 (40.9%) 0 (0%) 7 (35%) 0 (0%)
Total 22 (100%) 22 (100%) 20 (100%) 20 (100%)
Table 1 – Characteristic of type 2 DM-TB coinfection during observation period of study.
Parameters MET group Non MET group p (difference)
Ages (years old) 44.59  8.64 48.40  8.17 0.863
HbA1c (g/dL) 8.82  1.91 9.52  2.02 0.379
Oxygen saturation (SpO2) (%) 98.06  0.73 97.47  0.83 0.308
BUN (mg/dL) 0.95  0.16 0.93  0.13 0.980
Creatinine serum (U/L) 23.92  11.92 27.3  12.01 0.103
SGOT (U/L) 17.63  6.16 14.44  6.48 0.354
SGPT (U/L) 19.22  8.73 16.09  7.56 0.509
i n d i a n j o u r n a l o f t u b e r c u l o s i s x x x ( 2 0 1 8 ) x x x – x x x 3
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3.3.2. SOD
SOD contributes to the INH's mycobactericid effect and
inducing autophagy.4,26
Table 4 shows that SOD level before treatment between
MET group and non MET group were alike ( p > 0.005), thus it
shows that patients in both groups, before treatment, were in
similar stage of SOD. The differences before and after
observation period was signiﬁcant in MET group (p < 0.005)
while in non MET group was not. Moreover, compared to non
MET group, determination SOD change as the effect of MET
therapy during intensive period of anti-TB was not signiﬁcant
differences in MET group.
Based on those results, we concluded that MET, 1.000–
1.500 mg/day, was signiﬁcantly increased SOD activities which
it is enhanced M. tuberculosis eliminating process. However, the
different of SOD level after observation period in both groups
were not signiﬁcant changes. In our knowledge, SOD activity is
generated by the body and adjusted to the existing oxidant
levels,15 thus, this result phenomenon is due to SOD activity
triggered not only by MET induced AMPK but also by other
factors such oxidative stress, hyperglycemia associated ROS
and M. tuberculosis elimination process.11
In this study, elevated SOD levels were a synergistic effect
of MET and anti-TB therapy. Furthermore, high blood SOD
levels in the MET group showed that the oxidative stress in the
MET group was also high. The increased oxidative stress in this
study was the result of respiratory macrophage cell burst of M.
tuberculosis phagocytosis process in the blood.11,27 The increase
of SOD in this study is assumed as high intracellular killing
effect of macrophage cell on M. tuberculosis and is proven by
AFB smear reversion rate in MET group (100% as seen in
Table 2).
3.3.3. IFN-g
IFN-g is activated by Th1 to maintain IL-12 receptor and provide
protection against TB infection.28 Increased of IFN-g in chronic
TB infection is a cellular immune response. Currently, IFN-g
release assay (IGRA) is used as one of the tools of diagnosis of
latent TB infection and IFN-g elevation is one of the indicators of
successful treatment in active TB infection.29,30 Moreover, IFN-g
plays important key in autophagy.21,30
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Table 3 – Microtubule-associated Protein1 Light Chain 3B
(MAP1LC3B) level of type 2 DM-TB patient before and after
observation period.
MAP1LC3B level MET
group
Non MET
group
Between
groups
differences
xÈSD xÈSD
Before 1247.7  551.5 1571.6  477.7 0.062
After 1859.4  47.3 1343.6  607.9 0.004
Before and
after
differences
p = 0.000 p = 0.830
Table 4 – Superoxide dismutase (SOD) level of type 2 DM-
TB patient before and after observation period.
SOD's level MET
group
Non MET
group
Between
groups
differences
xÈSD xÈSD
Before 47.63  25.76 86.23  18.63 0.427
After 57.33  27.34 61.73  22.57 0.138
Before and
after
differences
p = 0.000 p = 0.343
Table 5 – Interferon (IFN)-g level of type 2 DM-TB patient
before and after observation period.
IFN-g level MET
group
Non MET
group
Between
groups
differences
xÈSD xÈSD
Before 1116.4  650.2 1430.9  680 0.072
After 1857.4  48.77 1313.7  617.6 0.004
Before and
after
differences
p = 0.000 p = 0.899
Table 6 – Interaction between metformin, level of SOD, MAP1LC3B, IFN-g, and AFB smears reversion.
No. Variable Beta (b) p
1. Metformin ! IFN-g 0.621 0.000a
2. Metformin ! SOD 0.681 0.000a
3. Metformin ! MAP1LC3B 0.636 0.000a
4. Metformin ! AFB reversion 0.386 0.012a
5. IFN-g ! MAP1LC3B 0.875 0.000a
6. SOD ! MAP1LC3B 0.441 0.004a
7. IFN-g ! AFB reversion 0.295 0.015a
8. SOD ! AFB reversion 0.267 0.122
9. MAP1LC3B ! AFB reversion 0.303 0.021a
Beta (b): regression coefﬁcient, shows the relationship between independent variables to dependent variable (increase or decrease, negative
value means inhibit).
p: probability signiﬁcance value, is stated signiﬁcant; signiﬁcant when p value < 0.05.
!: affect to.
a Meaningful.
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Table 5 shows that IFN-g level before treatment between
MET group and non MET group were alike ( p > 0.005), thus it
shows that patients in both groups, before treatment, were in
similar stage of IFN-g. The differences before and after
observation period was signiﬁcant in MET group (p < 0.005)
while in non MET group was not. Moreover, compared to non
MET group, IFN-g elevation as the effect of MET therapy during
intensive period of anti-TB was also signiﬁcant differences.
Thus, we concluded that MET improves autophagy and it
results 100% AFB smear reversion rate in MET group (as seen in
Table 2).
3.4. Interaction between metformin, level of SOD,
MAP1LC3B, IFN-g, and AFB smears reversion
Using regression category, we concluded that AFB smear
reversion in this study was inﬂuenced by MET through
autophagy activity and IFN-g, while SOD did not affect the
AFB smear reversion directly, but through the autophagy (as
seen in Table 6). Several studies related to the autophagy in TB
infection, suggest that SOD and IFN-g play important role in
autophagy21,25,31,32 and the results of this study support those
information.
4. Conclusion
Research and development of new host-directed therapies
aimed at improving clinical outcomes of TB patients, are now
beginning to be widely practiced in TB therapy strategies,
especially using immunomodulatory drugs. The high number
of resistance and failure of therapy in TB infection is one of the
reasons for the implementation of the activity. Glucocorticoid
and IL-12 drugs are ‘‘old’’ drugs used in new TB treatment
strategies.8,9,33
Some previous studies suggest that MET is an immune-
modulator that inhibits cancer cell proliferation stimulator,
insulin like growth factor (IGF) and activation of PI3K-AKT. The
mechanism of inhibition that is the reason Metformin is used
for the prevention and adjuvant therapy for cancer, including
breast cancer, ovarian cancer, colorectal cancer and prostate
cancer.34,35 Thus, several comprehensive studies in silico,
in vitro and animal in vivo also suggest that MET may increase
the efﬁcacy of anti-TB treatment,12,25 however, no human
studies have supported it. MET has additive effects on anti-TB
due to: (1) MET may increase the expression of organic cation
transporter (OCT)-1 rifampicin were instrumental M. tubercu-
losis inhibition of transcription10; (2) MET, based on the results
of this study and some previous research, could increase the
SOD to prevent resistance to isoniazid.9,11,16
This study provides data on patient clinical changes, the
AFB smear reversion in DM-TB coinfection patients (Table 2) so
that it can be concluded that MET uses as a insulin
combination and has additional effect in enhance anti-TB
efﬁcacy. Moreover, MET, based on the results of this study and
some previous studies, may be concluded as autophagy
inducer or mTOR inhibitor. Nevertheless, the mechanism of
action of metformin at the molecular level involving phago-
somes and lysosomes remains unknown yet in detail and
requires further study. In the even of MET associated
autophagy through the phagosome, it may increase the
efﬁcacy of pyrazinamide induced intracellular phagocytosis
of M. tuberculosis,8,36 that need further study.
As preliminary study, this result need to be continued in
subsequent studies to develop more effective TB treatment
strategies and the development of new adjuvant therapy that
works as an immune-modulator by emphasizing the improve-
ment of SOD, autophagy and have less minimal gastrointesti-
nal side effects and the likelihood of more minimal lacto-
acidosis. As conclusion, MET has the potential of being an
additive combination therapy to enhance the bactericidal
effect of anti-TB on DM-TB coinfection patients. Metformin
enhances the effects of anti-TB and insulin therapy in
increasing the AFB smear reversion by increasing autophagy.
MET was also relatively safe for DM-TB coinfection patients
due to its result in not elevated lactate levels.19
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